Please login to the form below

Not currently logged in
Email:
Password:

Royalty Pharma

This page shows the latest Royalty Pharma news and features for those working in and with pharma, biotech and healthcare.

Forest Labs agrees $1.46bn deal to buy Furiex

Forest Labs agrees $1.46bn deal to buy Furiex

Rights to these products will be sold on to Royalty Pharma AG for around $415m, helping to offset the Furiex purchase by around $315m, although Forest said the main Furiex deal

Latest news

  • 2013 - biotech boomed 2013 - biotech boomed

    2013 - biotech boomed. The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines. ... battle which had seen Elan resort to legal action to fend off hostile bids from US company Royalty Pharma.

  • Royalty Pharma buys bigger Tecfidera interest Royalty Pharma buys bigger Tecfidera interest

    Royalty Pharma buys bigger Tecfidera interest. Agrees $510m deal with Biogen Idec for IP share of multiple sclerosis drug. ... Royalty Pharma negotiated a similar earn-out agreement with former Fumapharm shareholders in May 2012, paying around $761m on

  • Perrigo agrees $8.6bn deal to buy Elan Perrigo agrees $8.6bn deal to buy Elan

    Perrigo agrees $8.6bn deal to buy Elan. Ends months of speculation about fate of Irish pharma company. ... from US company Royalty Pharma.

  • FDA fast-tracks Elan’s Alzheimer’s drug FDA fast-tracks Elan’s Alzheimer’s drug

    These deals have yet to provide Elan with definitive pipeline prospects, and have been roundly criticised by Royalty Pharma – a firm that specialises in buying up intellectual property assets in the ... Royalty's interest in Elan was first noted in

  • Elan blocks Royalty takeover - for now Elan blocks Royalty takeover - for now

    Elan blocks Royalty takeover - for now. After rejecting Royalty Pharma's bid Elan wants greater clarity on the deal. ... lowball revised tender offer and deliver the company into Royalty Pharma's hands at an unfair and inadequate price.”.

More from news
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... In parallel Royalty Pharma also purchased $75m of Immunomedics shares at $17.15 per share (15% premium).

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... Sale of Priority Review Voucher (PRV). 125.

  • Deal Watch March 2016 Deal Watch March 2016

    Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Reckitt Benckiser(RB) is spinning out its pharma business unit, under the name Indivior. ... On a mission. Continuing its trend of helping companies monetise their future income streams, Royalty Pharma is buying royalties in Vertex Pharmaceutical's

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics